NeuroViVe Announces Poor Results on its Mitochondrial CicloMulsion Investigational Drug in Acute Myocardial Infarction Patients

NeuroVive Pharmaceutical AB, a company focused on the treatment of acute conditions linked to mitochondria, recently announced that its investigational product CicloMulsion® did not meet the primary clinical endpoint in the phase III CIRCUS trial in patients who have experienced a particular type of heart attack called ST-segment elevation…

NeuroVive Awaiting Topline Results of CIRCUS Trial with CicloMulsion

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, is currently conducting a Phase III clinical study (“CIRCUS”) with its lead candidate CicloMulsion® in patients with ST-segment elevation acute myocardial infarction (STEMI). Topline results are expected in this quarter, which is sooner than expected, and will determine the success of meeting…